Indian Journal of Dermatology (Jan 2009)

Efficacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin structure infections in Indian patients

  • Manaktala Charu,
  • Singh Amit,
  • Verma Manish,
  • Sachdeva Asheesh,
  • Sharma Himanshu,
  • Roy Arjun,
  • Jalali R,
  • Gowrishankar R,
  • Kumar A,
  • Kumar A,
  • Jayaraman A,
  • Swarnkar B,
  • Srinivas C,
  • Nayak Chitra,
  • Duttaroy D,
  • Umrigar D,
  • Jesudanam Madhuri,
  • Maheshwari N,
  • Shetty P,
  • Singh R,
  • Ghate S,
  • Sacchidanand S,
  • Tolat S,
  • Bhoira Salman,
  • Marfatia Y

Journal volume & issue
Vol. 54, no. 4
pp. 350 – 356

Abstract

Read online

Background: Uncomplicated skin and skin structure infections (uSSSI) are commonly encountered community-acquired infections and are typically confined to the superficial layers of the skin. Hence, they seldom lead to the destruction of skin structures. Aims: To evaluate the efficacy and tolerability of cefditoren pivoxil in uSSSI in Indian patients. Methods: One hundred and seventy-eight patients diagnosed with uncomplicated SSSI were enrolled in this randomized, comparative, multicentric study. Patients received either cefditoren pivoxil or cefdinir for ten days. Efficacy was assessed both clinically and microbiologically. Safety evaluation consisted of reporting of type, frequency, severity, and causal relationship of adverse events. Results: One hundred and fifty-one patients completed the study. Clinical and bacteriological efficacy of cefditoren pivoxil was comparable to that of cefdinir in the treatment of uSSSI. One hundred and five patients were eligible for per protocol (PP) analysis of bacteriological outcome and clinical efficacy. Clinical cure or improvement was achieved in 98.00% patients treated with cefditoren pivoxil and 98.18% patients treated with cefdinir. In the modified Intent to Treat (mITT) patient population, clinical cure or improvement was recorded in 97.33% patients treated with cefditoren pivoxil and 96.20% patients treated with cefdinir. Microbiological eradication (or presumed eradication) was recorded in 88.00% patients treated with cefditoren pivoxil and 94.55% patients treated with cefdinir. The above differences in the outcome rates between the two drugs were not statistically significant. Six adverse events (AEs) (two in cefditoren group and four in cefdinir group) were reported in this study. Conclusion: Cefditoren pivoxil 200 mg b.i.d. was effective and well tolerated in the treatment of uSSSI.

Keywords